TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18291727

Group type: EXPERIMENTAL
Intervention: Paravertebral or high-thoracic epidural analgesia combined with sedation or light anesthesia
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia and morphine analgesia
Number of subjects: 1100
Study: 16878680

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri formulation LR-1 (2 x 10(8) CFU per day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri formulation LR-2 (2 x 10(8) CFU per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12874466

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (0.9 g thrice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10672134

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation (magnesium sulphate 8 g in 250 mL of 5% glucose)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (250 mL of 5% glucose)
Number of subjects: 68
Study: 9083599

Group type: EXPERIMENTAL
Intervention: Behavior skills training intervention (BST)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Educational intervention (EC)
Number of subjects: 117
Study: 8410923

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lisinopril vs Placebo
Number of subjects: 27
Study: 3776903

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous 5-FU
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous 5-FU with pelvic irradiation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 66
Study: 31917837

Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 4994

Group type: COMPARATOR
Intervention: HIV-negative men
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 4994
Study: 28970291

Group type: EXPERIMENTAL
Intervention: TIPS (transjugular intrahepatic portosystemic shunt)
Number of subjects: 49

Group type: COMPARATOR
Intervention: EBL plus propranolol (EBL+drug)
Number of subjects: 49
Study: 27495269

Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 78
Study: 24842135

Group type: EXPERIMENTAL
Intervention: Cardiac output-guided hemodynamic therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours following surgery (n=368)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Usual care (n=366)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Meta-analysis of 38 trials including this study
Number of subjects: 734
Study: 23021114

Group type: EXPERIMENTAL
Intervention: Screw‐based dental distractor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous force coil spring distractor
Number of subjects: 30
Study: 20573348

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (40 mg vaginal application once weekly for 6 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Metronidazole (500 mg oral treatment twice daily for 7 days)
Number of subjects: 49
Study: 17971530

Group type: EXPERIMENTAL
Intervention: CVD (cyclophosphamide, vincristine, and dexamethasone)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: KA/VE (ketoconazole plus doxorubicin alternating with vinblastine plus estramustine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TEC (weekly paclitaxel, estramustine, and carboplatin)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TEE (paclitaxel, estramustine, and etoposide)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Second-line regimens (CVD, KA/VE, TEC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 150
Study: 15126741

Group type: EXPERIMENTAL
Intervention: Laser myringotomy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ventilation tubes
Number of subjects: 208
Study: 11239907

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9478315

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (341 mg once a week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Natural Progesterone (50 mg/day)
Number of subjects: 80
Study: 8176180

Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin eyedrops
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen eyedrops
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 3295212

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 199
Study: 30685751

Group type: EXPERIMENTAL
Intervention: Near-peer tutors (newly graduated doctors)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Staff tutors
Number of subjects: 241
Study: 29665062

Group type: EXPERIMENTAL
Intervention: 1% JTE-052 ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3% JTE-052 ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-application
Number of subjects: 0
Study: 26854386

Group type: EXPERIMENTAL
Intervention: epoc® blood analysis system
Number of subjects: 40
Study: 24767638

Group type: EXPERIMENTAL
Intervention: PCEA with 1 mg/mL ropivacaine and 2 μg/mL fentanyl (Group A)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: PCEA with 0.8 mg/mL bupivacaine (Group B)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: CEI with 1 mg/mL ropivacaine (Group C)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: CEI with 0.8 mg/mL bupivacaine (Group D)
Number of subjects: 480
Study: 22364262

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day) with ursodeoxycholic acid (UDCA) (600 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 85
Study: 20698351

Group type: EXPERIMENTAL
Intervention: Topical difluoromethylornithine (DFMO)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topical Triamcinolone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topical difluoromethylornithine (DFMO) + Triamcinolone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Eucerin + Eucerin (double placebo)
Number of subjects: 102
Study: 17442512

Group type: EXPERIMENTAL
Intervention: Kangxin capsule
Number of subjects: 56
Study: 16100159

Group type: EXPERIMENTAL
Intervention: lipo-PGE1 (10 microg bid for 14 days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: lipo-PGE1
Number of subjects: 49
Study: 11829697

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Both groups (hormone therapy and placebo)
Number of subjects: 2763
Study: 10510146

Group type: EXPERIMENTAL
Intervention: L‐NMMA (4 mg kg‐1 bolus, with 4 mg kg‐1 infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5 microg kg‐1 min‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8731849

Group type: EXPERIMENTAL
Intervention: 200mg vitamin C twice a day for 3 months
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo tablets for 3 months
Number of subjects: 316
Study: 16296711

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg once daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diltiazem (60-120 mg three times daily)
Number of subjects: 80
Study: 6111965

Group type: EXPERIMENTAL
Intervention: Carbonated beverage with syrup of ipecac
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water with syrup of ipecac
Number of subjects: 24
Study: 31888766

Group type: EXPERIMENTAL
Intervention: Maize flour enriched through agro-biofortification with Se
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control flour not enriched with Se
Number of subjects: 360
Study: 28364426

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) combined with zolpidem as needed
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) with zolpidem tapered
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) with continued zolpidem as needed
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Extended Cognitive-Behavioral Therapy (CBT)
Number of subjects: 160
Study: 25594222

Group type: EXPERIMENTAL
Intervention: 3-hour oral glucose tolerance test (OGTT) values (fasting, 1-hour, 2-hour, and 3-hour)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Fasting glucose between 85 and 94 mg/dL
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Fasting OGTT < 95 mg/dL
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Other OGTT values (1-hour, 2-hour, 3-hour)
Number of subjects: 1360
Study: 24093709

Group type: EXPERIMENTAL
Intervention: Modified Stoppa approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ilioinguinal approach
Number of subjects: 60
Study: 21872979

Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy in patients with IHD
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy in patients without IHD
Number of subjects: 1747
Study: 19657924

Group type: EXPERIMENTAL
Intervention: Frequency format
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-in-N format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High numeracy levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low numeracy levels with frequency format
Number of subjects: 0
Study: 18068613

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (no additional drug)
Number of subjects: 77
Study: 15168319

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 11440064

Group type: EXPERIMENTAL
Intervention: Standardized-patient (SP) cases on cancer screening and literacy, incorporated into the curriculum for second-year students.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) case on breast cancer screening and literacy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical practice examination on colorectal cancer screening and literacy.
Number of subjects: 0
Study: 9649984

Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 5 mL saline (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 10 mL saline (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 15 mL saline (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 3 mL saline (Group A)
Number of subjects: 60
Study: 7662126

Group type: EXPERIMENTAL
Intervention: freeze-dried plasma containing a high titre of anti-lipopolysaccharide (anti-LPS) IgG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 2225184

Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 40

Group type: COMPARATOR
Intervention: perphenazine
Number of subjects: 40
Study: 282079

Group type: EXPERIMENTAL
Intervention: Chlorthalidone, frusemide, or mefruside for 4 weeks (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Chlorthalidone for 6 weeks (group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Chlorthalidone, frusemide, or mefruside
Number of subjects: 29
Study: 31752521

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (225 mg at baseline, weeks 4 and 8)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Fremanezumab (both monthly and quarterly)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study: 30914002

Group type: EXPERIMENTAL
Intervention: Coordinated specialty care
Number of subjects: 75
Study: 27552353

Group type: EXPERIMENTAL
Intervention: Occluded tracheostomy tubes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open tracheostomy tubes
Number of subjects: 20
Study: 25591873

Group type: EXPERIMENTAL
Intervention: Diazoxide (7 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22739821

Group type: EXPERIMENTAL
Intervention: Yogic breathing and muscle-strengthening and flexibility exercises for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinematics motion analysis (exploratory)
Number of subjects: 15
Study: 20729034

Group type: EXPERIMENTAL
Intervention: Air inflated cuffs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: O₂‐N₂O mix inflated cuffs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Saline solution inflated cuffs
Number of subjects: 90
Study: 18191817

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15671432

Group type: EXPERIMENTAL
Intervention: Calfactant (2 doses of 80 mL/m2)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (equal volume of air)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Calfactant and Placebo
Number of subjects: 153
Study: 12972855

Group type: EXPERIMENTAL
Intervention: Interpretive group therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both therapies (interpretive and supportive)
Number of subjects: 61
Study: 10228057

Group type: EXPERIMENTAL
Intervention: Nevirapine-containing regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nelfinavir, saquinavir, abacavir, and nevirapine
Number of subjects: 20
Study: 9033201

Group type: EXPERIMENTAL
Intervention: Laser Doppler vasomotor reflex testing
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 2064719

Group type: EXPERIMENTAL
Intervention: Alcohol challenge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 24
Study: 6388832

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose melphalan/prednisone (MP) treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Human leukocyte interferon (IFN) administration
Number of subjects: 130
Study: 31707816

Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild Therapeutic Hypothermia (THT)
Number of subjects: 0
Study: 29682995

Group type: EXPERIMENTAL
Intervention: Combination of isosorbide dinitrate spray and chitosan gel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chitosan gel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26972635

Group type: EXPERIMENTAL
Intervention: Traditional resistance training (TD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pyramidal resistance training (PR)
Number of subjects: 25
Study: 24470342

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 23110494

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg) biannually
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Snail control with niclosamide
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Behaviour change interventions
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Health system, water and sanitation infrastructure improvements
Number of subjects: 4500
Study: 21050332

Group type: EXPERIMENTAL
Intervention: Structured reminiscence protocol offered twice weekly for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured reminiscence protocol (duration longer than 3 weeks)
Number of subjects: 0
Study: 17379055

Group type: EXPERIMENTAL
Intervention: Test formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reference formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Number of subjects: 29
Study: 17219281

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy in women
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy in men
Number of subjects: 132

Group type: COMPARATOR
Intervention: Open appendectomy in men
Number of subjects: 132
Study: 15682350

Group type: EXPERIMENTAL
Intervention: TPV 250 mg to 1250 mg twice daily for 11 days followed by RTV 100 mg for 21 days
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: TPV 500 mg and 750 mg with RTV 100 mg or 200 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All TPV/r combinations
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 95
Study: 10623704

Group type: EXPERIMENTAL
Intervention: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) with l‐OHP (125 mg/m(2), as a 6‐hour infusion)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) without l‐OHP
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5‐day course of chronomodulated 5‐FU and LV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5‐day course of chronomodulated 5‐FU and LV with l‐OHP
Number of subjects: 200
Study: 9361574

Group type: EXPERIMENTAL
Intervention: Special Intervention (training program)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care condition (control)
Number of subjects: 31
Study: 1337070

Group type: EXPERIMENTAL
Intervention: Azithromycin, 250 mg bd for 2 days followed by 250 mg od for 8 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg bd for 14 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin, 1 million IU tds for 14 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 3986069

Group type: EXPERIMENTAL
Intervention: Extradural morphine (group II)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Extradural morphine and bupivacaine (group III)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bupivacaine alone (group I)
Number of subjects: 17
Study: 30665814

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with sequential stereotactic body radiotherapy (SBRT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with concomitant stereotactic body radiotherapy (SBRT)
Number of subjects: 18
Study: 29061617

Group type: EXPERIMENTAL
Intervention: HEART score calculation by physicians in daily practice
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Incorrect HEART score
Number of subjects: 1752
Study: 26186702

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler monitor (ODM, CardioQ‐ODM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulse power wave analysis (PPA, LiDCOrapid)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PPA group
Number of subjects: 21
Study: 23872048

Group type: EXPERIMENTAL
Intervention: Integrated motor imagery practice
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control treatment (executed exercises to improve upper extremity function)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 23
Study: 21818648

Group type: EXPERIMENTAL
Intervention: Discussion of family health history with a physician
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Perception of responsibility for initiating discussions
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Having a discussion with a physician
Number of subjects: 632
Study: 19553404

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infused over 1 hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infused over 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doripenem 1000 mg infused over 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All regimens of doripenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group in Study 1)
Number of subjects: 0
Study: 18225515

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using Photosens (aluminum phthalocyanine) intravenously injected at a dose of 0.05 mg/kg, with laser irradiation at 675 nm and exposure light dose of 120 J/cm2, total light dose not greater than 500 J/cm2.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Drug therapy (control group).
Number of subjects: 32
Study: 15066462

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d orally)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11774805

Group type: EXPERIMENTAL
Intervention: Educational intervention including patient education, self-monitoring of blood glucose, and determination of HbA1c levels.
Number of subjects: 416

Group type: COMPARATOR
Intervention: Customary care (control group).
Number of subjects: 416
Study: 9571510

Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound treatment, started immediately after plaster removal
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no ultrasound treatment)
Number of subjects: 38
Study: 8150641

Group type: EXPERIMENTAL
Intervention: Music and muscle relaxation interventions (two or three 30-minute sessions of audiotape interventions with light classical music and verbal instructions for muscle relaxation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 56
Study: 2834976

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg acebutolol 5 min after induction of anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without acebutolol treatment
Number of subjects: 20